Clinical trial
AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
NCT00243061 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00243061 |
|---|---|
| Title | AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma |
| Official title | A Phase II Study of AZD2171 in Previously Untreated Patients With Metastatic or Recurrent Malignant Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acral Lentiginous Malignant Melanoma, Ciliary Body and Choroid Melanoma, Medium/Large Size, Small Size, Extraocular Extension Melanoma, Intraocular Melanoma, Iris Melanoma, Lentigo Maligna Malignant Melanoma, Recurrent Melanoma, Stage and 2 more |
| Intervention type | Drug |
| Interventions | cediranib maleate |
| Enrollment | 24 |
| Start date | Jan 1, 2006 |
| Primary completion | Mar 1, 2012 |
| Completion | Mar 1, 2012 |
| First posted | Oct 21, 2005 |
| Last update posted | Aug 27, 2018 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: